Transpara Density

by Screenpoint Medical B.V.  · Based in Netherlands → — We are the Breast AI Company.
Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

Transpara® Density is an AI-powered software application designed to provide accurate and consistent breast density reporting in mammography. It addresses the challenges breast density poses in mammography by combining two tailored algorithms: a BI-RADS-like breast density assessment and a volumetric breast density (VBD) assessment. These algorithms work in tandem to reduce variability, ensure compliance with reporting standards like the MQSA Final Rule in the USA, and enhance efficiency and consistency in breast density assessment. Transpara Density is intended to aid healthcare professionals in assessing breast tissue composition and is compatible with both 2D Full-Field Digital Mammography (FFDM) and 3D Digital Breast Tomosynthesis (DBT) systems.

The volumetric breast density (VBD) assessment, trained and refined with a ground truth dataset from breast MRI, has been shown in clinical studies to be a strong predictor of breast cancer risk. The results from Transpara Density are available directly within existing radiology workflows, integrating seamlessly with current systems and platforms.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated BI-RADS-like breast density assessment (5th Ed.)
  • Volumetric Breast Density (VBD) assessment
  • Compatibility with FFDM and DBT mammograms
  • Integration into existing radiology workflows and PACS systems
  • Reduces variability in density reporting
  • Aids in compliance with reporting standards (e.g., MQSA Final Rule)
  • Trained with ground truth dataset from breast MRI
  • Provides breast volume in cmu00b3
  • Supports 2D and 3D mammograms
  • Objective density evaluation

Use Cases

  • Automated breast density reporting for mammography screening
  • Ensuring compliance with breast density reporting regulations
  • Enhancing consistency and efficiency in breast tissue composition assessment
  • Supporting radiologists in identifying women with dense breasts for potential supplemental screening
  • Integrating AI-driven density assessment into existing breast imaging workflows

What Physicians Need to Know

Key Capabilities
Automated assessment of both BI-RADS-like breast density categories and volumetric breast density (VBD). Compatible with both 2D Full-Field Digital Mammography (FFDM) and 3D Digital Breast Tomosynthesis (DBT) systems. Provides breast volume as an output.
Clinical Utility
Aids healthcare professionals in consistent and accurate breast tissue composition assessment, reducing inter- and intra-radiologist variability. Supports compliance with regulatory requirements such as the MQSA Final Rule in the USA for density reporting. Volumetric breast density is a strong predictor of breast cancer risk and is incorporated into risk assessment tools like the IBIS Breast Cancer Evaluation Tool (Tyrer-Cuzick V8).
Integration Options
Designed for seamless integration directly into existing radiology workflows and compatible with various PACS systems, AI platforms, and major imaging systems from vendors including Hologic, GE, Siemens, and Fujifilm. Can be integrated through enterprise AI platforms like Aidoc's aiOSu2122 and Ferrum Health's Model Hub.
Compliance Status
FDA cleared (K241831, K232096 for Transpara 2.1) and CE Marked (0344). Holds regulatory clearance in over 40 countries globally. Supports compliance with the MQSA Final Rule in the USA.
Pricing Model
Available as an on-premises subscription model or with a multi-year license. Pricing is typically based on the volume and type of study (2D FFDM or 3D DBT). Some providers offer it as an out-of-pocket add-on service.
User Experience
Results are delivered directly within the existing reading workflow, aiming to reduce variability and provide consistent, confident assessments. The automated AI assessment offers objective density evaluation.
Support Quality
ScreenPoint Medical provides customer support via email and phone for EMEA, USA, and APAC regions. They also work with IT teams to ensure seamless deployment.
Implementation Complexity
Designed for seamless deployment within existing workflows. Requires embedding in a software application that generates standardized outputs (e.g., DICOM) and communicates with external devices (e.g., PACS systems). Supports validation against local data prior to full clinical implementation.
Evidence Base
Trained and refined using a ground truth dataset from breast MRI. Performance tests demonstrate high agreement with radiologist visual assessments, meeting standalone performance requirements. Studies show a Pearson correlation coefficient of 0.908 with VBD from breast MRI. For dense vs. non-dense classification, it has a sensitivity of 87.3% and specificity of 90.4%. The broader Transpara suite is backed by over 55 peer-reviewed publications and is the only breast AI solution validated by a randomized controlled trial (MASAI study). It performs similarly well in dense and non-dense breasts.
Physician Tip

Utilize both BI-RADS-like and volumetric density assessments provided by Transpara Density for comprehensive patient risk stratification and personalized screening recommendations. Leverage the automated, consistent reporting to enhance efficiency and ensure compliance with regulatory requirements like MQSA. Integrate Transpara Density into existing mammography reading workflows to reduce variability and improve the consistency of breast density assessment. Consider the volumetric breast density output as a strong predictor of breast cancer risk, especially when used in conjunction with other clinical risk assessment tools.

Transpara Density is engineered for seamless integration into existing radiology workflows, supporting various PACS systems, AI platforms, and major imaging modalities (FFDM and DBT) from vendors such as Hologic, GE, Siemens, and Fujifilm. It can also be deployed through enterprise AI platforms like Aidoc's aiOSu2122 and Ferrum Health's Model Hub, facilitating a unified AI experience and streamlined management within a healthcare system's IT infrastructure. The system is designed to provide results directly within the user's current workflow, minimizing disruption.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
  • Annual subscription; Site or enterprise licenses available; pricing based on the volume and type of study carried out (2D FFDM or 3D DBT); typical prices ranged from £0.60 to £3.00 per exam in 2021
DeploymentAvailable directly within existing workflows; integrates seamlessly across PACS systems, AI platforms, and imaging solutions; deployed locally on dedicated hardware or virtualized (virtual machine, Docker).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Transpara Density received FDA 510(k) clearance (K232096) on December 11, 2023. It is a software application that uses deep learning AI algorithms to automatically determine volumetric breast density (VBD), breast volume, and an ACR BI-RADS 5th Edition breast density category to aid healthcare professionals in assessing breast tissue composition. It is not a diagnostic aid.

Integrations
EHR Not specified
Specialties Radiology

What the Web Says

Transpara Density is an FDA-cleared and CE-marked AI-powered tool that automates breast density assessment for both 2D and 3D mammograms, integrating into existing radiology workflows. It provides both volumetric breast density and BI-RADS-like composition, aiming for consistency in analysis and reporting. The software is part of the broader Transpara Breast AI Suite, which also includes modules for cancer detection and temporal comparison.

Overall: Positive

Strengths

  • Automates breast density assessment for 2D and 3D mammograms, providing consistent and clear results.
  • Integrates seamlessly into existing radiology workflows and is compatible with major mammography systems.
  • Aids in risk assessment and can contribute to risk-adapted screening strategies.
  • Backed by clinical studies and has regulatory clearances in multiple countries.
  • Can help streamline workflow and potentially reduce radiologist workload when used as part of the Transpara Breast AI suite.
  • Provides objective and reproducible volumetric measures useful for reporting and risk calculators.

Limitations

  • While AI systems show high performance, they may still perform lower than human double-reading in some aspects of cancer detection.
  • The definitive impacts on interval cancer rates and mortality require longitudinal follow-up.
  • Performance can vary with device manufacturer, demographics, and prevalence, necessitating local validation and calibration.
  • Some studies on the broader Transpara AI suite (which includes Density) indicate a potential for increased recall rates in certain scenarios.

Based on reviews from: ScreenPoint Medical (screenpoint-medical.com), HealthAidb, Innolitics, MDEdge, RSNA Journals (Radiology), PMC (PubMed Central)

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Transpara Density

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Applied Radiology
ScreenPoint Medical's Transpara Breast AI Suite Joins Ferrum Health's Model Hub to Support Scalable, Trusted AI Deployment
ScreenPoint Medical's Transpara Breast AI Suite, including Transpara Density, has been integrated into Ferrum Health's Model Hub to facilitate scalable and trusted AI deployment in radiology. This partnership aims to help radiology teams adopt AI with confidence, advancing earlier detection and more equitable screening outcomes.
2026-01
Medical Outfitters
Transpara Density AI Software | Medical Outfitters
Transpara Density is FDA cleared and CE marked for 2D and 3D mammography, designed to fit into existing mammography reading workflows by running density algorithms in parallel and delivering results in current platforms. It supports breast density reporting across screening and diagnostic mammography, aligning with MQSA Final Rule requirements in the US.
2026-06
ScreenPoint Medical
ScreenPoint Medical Showcases Transpara Breast AI Suite at RSNA 2025
ScreenPoint Medical showcased its Transpara Breast AI suite, including Transpara Density, at RSNA 2025, highlighting its role in earlier cancer detection, reduced radiologist workload, and improved program performance. The company announced that Transpara Breast AI has processed over 11 million mammograms and is deployed in over 30 countries.
2025-11
Constat
Transpara Density 1.0.0 (K232096) u2014 FDA 510(k) evidence - Constat
Transpara Density 1.0.0 received FDA 510(k) clearance (K232096) on December 11, 2023. The software utilizes deep learning AI algorithms to automatically determine volumetric breast density (VBD) and an ACR BI-RADS 5th Edition breast density category to assist healthcare professionals in assessing breast tissue composition.
2026-07
PRNewswire
ScreenPoint Medical Secures $16M to Lead the Next Phase of AI in Breast Cancer Care
ScreenPoint Medical announced $14 million in new funding from existing investors and $2 million in research grants to support product development and international expansion of its Transpara breast AI solutions. This funding follows groundbreaking research, including the MASAI randomized controlled trial, which showed favorable outcomes for Transpara in cancer detection and workload reduction.
2026-04
SPIE Digital Library (Journal of Medical Imaging)
Assessing mammographic density change within individuals across screening rounds using deep learningu2013based software
A study published in the Journal of Medical Imaging in August 2025 utilized Transpara Density software to assess mammographic density changes within individuals across screening rounds. The study found a statistically significant decrease in mean volumetric breast density (VBD%) between two examinations, with more pronounced declines in women with initially denser breasts.
2025-08
unknown
Revolutionizing Oncology Through Artificial Intelligence and Precision Medicine
Transpara Density 1.0.0 was among the specific FDA-approved AI-assisted medical devices and software for early cancer detection between July 2023 and June 2024. AI-driven systems like Transpara Density are improving the accuracy and efficiency of diagnostics by identifying subtle patterns in medical data.
2025-06
ScreenPoint Medical
ScreenPoint Medical expands in Spain with SACYL - EUSOBI 2025
ScreenPoint Medical partnered with Sacyl, the healthcare services system of the Castilla y Leu00f3n region in Spain, to bring Transpara Breast AI to approximately 15-17 breast cancer screening centers. Sacyl will implement Transpara Detection, Transpara Density, and Transpara Temporal Comparison algorithms to improve cancer detection and efficiency.
2025-09

Videos

Product demos, reviews, and walkthroughs for Transpara Density.

Loading videos...

View all on YouTube

Frequently Asked Questions

Transpara Density is designed to integrate directly into current mammography reading environments and PACS systems, providing automated breast density assessment. It offers both BI-RADS-like breast composition categories and volumetric breast density (VBD) assessments for both FFDM and DBT images, aiming to reduce variability and enhance consistency in reporting.
Transpara Density is FDA cleared in the USA and bears the CE mark in Europe, among other international clearances. It helps facilities comply with regulations like the MQSA Final Rule in the USA, which mandates informing patients about their breast density, by providing consistent and objective density assessments.
While Transpara Density is robust, studies indicate that human double-reading can still outperform AI systems in overall breast cancer detection. The performance of AI systems, including Transpara, can also show differences between dense and non-dense breasts, and there are limitations in evaluating performance across different racial or ethnic groups.
Alternative AI solutions for breast density assessment include ProFound AI by iCAD and Volpara TruDensity. While Transpara Density has demonstrated high agreement with radiologists' visual assessments and improves long-term risk prediction, comparative studies show varying performance, with some indicating other AI systems may perform differently in specific subgroups or overall cancer detection.
Transpara Density is typically available through a subscription model or a multi-year license. Pricing is often based on the volume and type of study performed (2D FFDM or 3D DBT). The cost usually includes installation, training, ongoing support, and future software upgrades, though customers are generally responsible for providing and maintaining the local hardware.
Transpara Density demonstrates high accuracy and reliability, with strong agreement with visual assessments by radiologists for classifying dense versus non-dense breasts. It is intended as a diagnostic aid to support healthcare professionals, providing a 'second pair of eyes' to enhance confidence and consistency, but patient management decisions should not be made solely based on AI analysis.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Cancer Copilot
Color Health
Oncology AI
Color Health's Cancer Copilot, built with OpenAI, helps oncologists and clinicians identify and order workup needs for recently diagnosed patients, aiming to speed up time to cancer treatment. This AI tool is designed to expand cancer expertise, speed decisions, and improve care, reducing a two-hour clinical task to 10 minutes with over 95% validated accuracy.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
Synapse Lung Nodule AI
Fujifilm Corporation
Oncology AI
Fujifilm's Synapse Lung Nodule AI is an AI software algorithm for detecting pulmonary nodules on CT imaging, aiming to support early detection and treatment of lung cancer.
RadOncAI
Informai (for RadOncAI product) / Global Network for AI in Radiation Oncology (for RadoncAI.net)
Oncology AI
RadOncAI is an AI solution by Informai designed to optimize and enhance radiation oncology workflows, improving efficiency and accuracy in treatment planning and delivery.
FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.

See all Oncology AI tools →

More from ScreenPoint Medical B.V.

ScreenPoint Medical
ScreenPoint Medical
Clinical Decision Support & Reference
ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
Transpara
ScreenPoint Medical B.V.
Clinical Decision Support & Reference
Transpara is an FDA-cleared AI solution by ScreenPoint Medical B.V. that enhances breast cancer detection and optimizes radiologist workflow for 2D and 3D mammography.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.